Time course of recurrent arrhythmias in clinical trials of catheter ablation for paroxysmal atrial fibrillation: A pooled analysis.

BACKGROUND

A follow-up duration of 1 year has been recommended to assess efficacy for atrial fibrillation (AF) ablation trials, but this duration lacks supporting evidence.

OBJECTIVE

This study evaluated the temporal dynamics of arrhythmia recurrence after catheter ablation of paroxysmal AF to inform optimal trial duration.

METHODS

We performed a systematic review of randomized clinical trials evaluating catheter ablation for the treatment of paroxysmal AF. The inverse Kaplan-Meier equation was used to reconstruct the time-to-event distribution for recurrence. The studies were pooled for analysis.

RESULTS

A total of 42 trials with 10,246 patients were included in the analysis. The pooled arrhythmia-free survival at 4, 6, 9, and 12 months after the index ablation procedure was 90.4% (95% confidence interval [CI], 89.8-90.9), 83.4% (95% CI, 82.7-84.1), 77.2% (95% CI, 76.4-78.0), and 72.8% (95% CI, 71.9-73.7) inclusive of a 3-month blanking period, respectively. Consequently, the timing of arrhythmia recurrences was front-loaded with 35.9% (CI, 34.9-36.8), 61.5% (CI, 59.9-63.0), and 85.2% of total recurrences (CI, 83.1-87.4) occurring by postablation months 4, 6, and 9, respectively. The 12-month arrhythmia-free survival could be predicted using the reported survival at 6 months with an absolute mean error of 4.2% (standard deviation, 2.8%).

CONCLUSION

The timing of arrhythmia recurrence after paroxysmal AF catheter ablation is nonuniform, with the relative yield of active monitoring decreasing as time increases from the index intervention. Shortening the postblanking period follow-up may allow for a less expensive clinical trial and enable earlier knowledge translation, without substantially compromising detection of recurrent arrhythmia.